Taiho Ventures, LLC
Corporate VCMenlo Park · Seed–Series B · 6 people tracked
Find your way into Taiho Ventures, LLC
187 people in our graph share verified history with the Taiho Ventures, LLC team — schools, employers, funds. One of them is your warm intro.
Investment thesis
Taiho Ventures aims to generate significant value by investing in the global biotech venture ecosystem while sourcing innovative science to benefit its parent company, Taiho Pharmaceutical Co., Ltd. As a corporate venture arm, it focuses on biotechnology and life-science innovation with a global mandate, connecting cutting-edge research and emerging companies to the strategic interests of the pharmaceutical parent.
Source: firm website, verified Aug 3, 2026.
Team · 6 people
from the firm's website & public directories
What they invest in
from 25 of 27 portfolio companiesBiotech ×25Healthtech ×12Medical Devices ×12AI & Machine Learning ×5Deep Tech ×2Digital Health ×1Longevity ×1
HQs:United States×14Japan×1Netherlands×1
Who they back
founder profiles across 10 portfolio companiesFounding team size:solo founder×52 founders×13 founders×34+ founders×1
Investments · 27 tracked
founders shown can be your intro pathBy year:2026 · 22025 · 22020 · 26 dated
Nextcure is a clinical-stage biopharmaceutical company developing immunotherapies targeting IO pathways, with a focus on oncology applications.
BiotechBeltsville, US
Michael Richman(Executive Officer, Director)Timothy Mayer(Executive Officer)inUdayan Guha(Executive Officer)inSteven P. Cobourn(Executive Officer)inSourav Kundu(Executive Officer)inKevin Shaw(Executive Officer)in
Co-investorsBay City CapitalCanaan PartnersLAVLilly Asia VenturesPfizer Venture InvestmentsQuan Capital+4 more
ORIC Pharmaceuticals is a clinical-stage oncology company developing therapies aimed at overcoming cancer treatment resistance, including innate, acquired, and bypass resistance.
BiotechHealthtechSouth San Francisco, US
Richard Heyman(Chairman, Founder, Scientific Advisory Board)inCharles Sawyers(Founder, Scientific Advisory Board)Scott Lowe(Founder, Scientific Advisory Board)Dominic Piscitelli(Chief Financial Officer)inPratik Multani(Chief Medical Officer)inJacob Chacko(President, Chief Executive Officer and Board Member)in
Co-investorsEcoR1 CapitalNew Enterprise Associates (NEA)Nextech InvestThe Column GroupOrbiMed
Anavo Therapeutics is a biopharmaceutical company using its IGNITE platform to develop phosphatase-targeted allosteric modulators, addressing drug targets previously considered undruggable.
BiotechHealthtechLeiden, NL
Birgit Zech(CEO)in
Co-investorsBioqube VenturesInkefM Ventures
Breakpoint Therapeutics is a biotech company focused on oncology drug discovery and development centered on DNA damage response (DDR) mechanisms.
BiotechHealthtechMedical Devices
Daniel Speidel(Co-founder & Managing Director)Jon Hollick(Co-founder & Managing Director)
Co-investorsBiotechnology Value FundMedicxi
cellvie develops Therapeutic Mitochondria Transplantation technology and products for patients requiring mitochondrial treatment.
BiotechHealthtechLongevityMedical Devices
Co-investorsBeiersdorf Innovation Fund
Light Horse Therapeutics is a drug discovery company applying scientific expertise and innovation to advance healthcare through collaborative development.
AI & Machine LearningBiotechMedical Devices
Co-investorsAbbVieMubadala CapitalVersant Ventures
Normunity develops biologic anti-cancer therapies that act at the interface of the immune system and tumors, targeting mechanisms tumors use to evade immune surveillance.
BiotechHealthtech
Rachel Humphrey(Founding Chief Executive Officer)inLieping Chen(Scientific Founder)Mitchell Keegan(Chief Development Officer)inWilliam LaRochelle(Chief Scientific Officer)inStacy M. Plum(Chief Technology Officer)
Co-investorsSanofi VenturesPfizer VenturesSamsara BioCapitalCanaan PartnersConnecticut InnovationsPfizer Venture Investments+4 more
Theolytics develops systemically deliverable immunotherapies based on oncolytic adenoviruses designed to target solid tumours and their supporting microenvironment.
BiotechHealthtech
Co-investorsEpidarex CapitalOxford Science EnterprisesSound BioventuresM Ventures
Dren Bio is a clinical-stage biopharmaceutical company developing novel antibody therapeutics designed to selectively eliminate pathogenic cells and disease-causing agents, with a pipeline targeting oncology, autoimmune diseases, immunology, and neurology.
BiotechHealthtechMedical DevicesFoster City, US
Nenad Tomasevic(Chief Executive Officer, Founder)
BoardIvan Trifunovich(Director)John Wesley(Director)
Board seatSakae Asanuma· per SEC Form D
Co-investors8VCAisling CapitalMission Bay CapitalMission BiocapitalOlive Tree CapitalSR One Capital Management+3 more
Arcus Biosciences develops combination cancer therapies, producing small molecules and antibodies designed to be combined and advanced from Phase 1 studies through commercialization.
Biotech
Juan Jaen(Founder)in
Co-investorsAisling CapitalDecheng CapitalDroia VenturesEcoR1 CapitalForesite CapitalSLVC+2 more
Crossbow Therapeutics develops TCR-mimetic antibody therapies designed to target cancer antigens by mimicking T-cell receptors, with a focus on treating solid tumors and hematologic malignancies.
AI & Machine LearningBiotechMedical DevicesCambridge, US
Alexander Nolte(Executive Officer)inDmitri Wiederschain(Executive Officer)in
BoardAlexandra Cantley(Director)inSakae Asanuma(Director)inBriggs Morrison(Executive Officer, Director, Promoter)inIrena Melnikova(Director)in
Co-investorsMPM BioImpactPfizer Venture InvestmentsBiotechnology Value FundMirae Asset Venture InvestmentPfizer VenturesPolaris Partners
Cullinan Therapeutics develops clinical-stage T cell engager therapies targeting autoimmune diseases and cancer, leveraging immune modulation expertise to advance high-impact therapeutic candidates.
BiotechDigital Health
Co-investorsLAVLilly Asia VenturesMPM BioImpactSchooner Capital
Delphia Therapeutics is a biotechnology company developing cancer medicines based on its activation lethality platform, aiming to create therapies effective on their own while combating resistance to targeted therapies.
BiotechHealthtechCambridge, US
Kevin Marks(Founder)in
Co-investorsGV (Google Ventures)Nextech InvestAlexandria
Epibiologics develops protein degradation medicines using protein sciences and antibody engineering capabilities.
BiotechMedical DevicesSan Mateo, US
Ann Lee-Karlon(Executive Officer, Director)inMitchell Mutz(Executive Officer, Director)James Wells(Director)
BoardSamuel Bjork(Director)inAlexandra Cantley(Director)inSeiji Miyahara(Director)in
Co-investorsAvego BioScience CapitalGV (Google Ventures)Mission BiocapitalNovartis Venture FundRoche Venture FundSamsara BioCapital+4 more
BiotechMedical DevicesNew Haven, US
Scott Phillips(Executive Officer)in
BoardTim Shannon(Manager)inLiam Ratcliffe(Manager)in
Co-investorsAccess BiotechnologyCanaan PartnersConnecticut InnovationsFrazier Life SciencesRA CapitalVida Ventures
A research-intensive biopharmaceutical company that develops medicines and vaccines.
BiotechHealthtechSouth San Francisco, US
Luke Nathaniel Walker(Executive Officer)Julie Eastland(Executive Officer, Director)in
BoardRonald Hunt(Director)Mark Chin(Director)Alan Colowick(Director)Jonathan Drachman(Director)
Co-investorsK2 HealthVenturesArix BioscienceLilly Asia VenturesMPM BioImpactNew Leaf Venture PartnersOrbiMed
Cambridge, MA biotech developing engineered tRNA "protein editing" therapeutics for nonsense-mutation diseases; reported shut down in 2025.
Cambridge, US
Leslie J Williams(Executive Officer, Director)
BoardBenjamin Chen(Director)Seiji Miyahara(Director)inSacha Mann(Director)David Moskowitz(Director)Steven Gillis(Director)in
Co-investorsARCH Venture Partners8VCTakeda Ventures
Magnet Biomedicine develops TrueGlue™, a molecular glue discovery platform for designing small molecule therapeutics that induce novel protein-protein interactions to treat cancer and immune disorders.
AI & Machine LearningBiotechMedical DevicesBoston, US
Benjamin F. Cravatt, PhD(Founder & Advisor)David A. Spiegel, MD, PhD(Founder & Advisor)Michael Rosbash, PhD(Founder & Advisor)Richa Saxena, PhD(Founder & Advisor)Stuart Schreiber, PhD(Founder & Advisor)Brian Safina(President & Chief Executive Officer)in
Co-investorsARCH Venture PartnersNewpath Partners
Orna Therapeutics develops RNA and lipid nanoparticle (LNP) based therapies for treating diseases including oncology and cell therapy applications.
AI & Machine LearningBiotechMedical Devices
Joe Bolen(Chief Executive Officer)Joe Bolen, Ph.D.(Chief Executive Officer)Hope D'Oyley-Gay, JD(Chief Legal Officer)Ciaran Lawlor, Ph.D.(Chief Operating Officer)Frank Neumann, M.D., Ph.D.(Chief Medical Officer)Siva Sakhamuri(Chief Technology Officer)in
Co-investorsAstellas Venture Management LLCMPM BioImpact
STORM Therapeutics is a clinical-stage biotechnology company developing small molecule drugs that target RNA modifying enzymes to reprogram cells through RNA biology.
BiotechHealthtechMedical Devices
Co-investorsCambridge Innovation CapitalFast Track InitiativeM VenturesPfizer Venture InvestmentsSeroba Life SciencesUTokyo Innovation Platform Co. Ltd.+1 more
Transition Bio applies methods from physics, chemistry, biology, and machine learning to study protein biophysics—including protein aggregation, self-assembly, and protein-protein interactions—for developing therapeutics targeting health and disease.
AI & Machine LearningBiotechDeep TechCambridge, US
Tuomas Knowles(Executive Director, Co-Founder & Chief Technology Officer)Samuel Cohen(Executive Director & Co-Founder)inG. Kelly Martin(Executive Chairman & Co-Founder)George Martin(Executive Officer, Director)inStephanie Torruella(Executive Officer)inPreet Makkar(Executive Officer)
Co-investorsNorthpond VenturesLifeforce CapitalMagnetic VenturesDolby Family Ventures
Vertero develops therapies for neurodegenerative diseases by targeting causative mechanisms in the peripheral nervous system rather than addressing symptoms alone.
BiotechHealthtechMedical Devices
Sarkis Mazmanian, PhD(Co-founder and Board Member)
Co-investorsAIFUTokyo Innovation Platform Co. Ltd.
Werewolf Therapeutics is a biotechnology company developing immunotherapy treatments for cancer.
BiotechHealthtechMedical DevicesWatertown, US
Daniel J. Hicklin(Founder, President, Chief Executive Officer, and Board member)Luke Evnin(Co-founder, Board member (Chairman))inDaniel Hicklin(Executive Officer, Director)David Cordo(Executive Officer)Alon Lazarus(Director)
BoardChristoph Westphal(Director)
Co-investorsDC Investment PartnersK2 HealthVenturesLongwood FundMPM BioImpactRA Capital
LiberoThera is a drug discovery company using cell-free membrane protein preparation technology and non-natural amino acid incorporation technology to develop antibody-based therapeutics, including antibodies targeting GPCRs such as anti-CCR8.
BiotechDeep Tech
Toru Kankein
Co-investorsMC Healthcare VenturesUTokyo Innovation Platform Co. Ltd.
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Normunity HoldingQuentisvisit www.incendiatx.com
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.
Exits · 2
2 IPOsNextCureNASDAQ: NXTCORIC PharmaceuticalsNASDAQ: ORIC
Portfolio news
latest coverage across their companies
Arcus Biosciences · pluang.com · Aug 19, 2026
ORIC Pharmaceuticals · manilatimes.net · Aug 7, 2026
NextCure · investing.com · Jul 15, 2026
Cullinan Oncology · investing.com · Jun 23, 2026
hC Bioscience · altss.com · Jun 3, 2026
Storm Therapeutics · bioxconomy.com · Apr 17, 2026
Dren Bio · biospace.com · Mar 2, 2026
Frequently asked questions
- How many investments has Taiho Ventures, LLC made?
- Taiho Ventures, LLC has 27 tracked investments, 2 of which have exited, including 4 dated in the last 24 months.
- What stage does Taiho Ventures, LLC invest at?
- Taiho Ventures, LLC invests at the Seed, Series A, Series B stages.
- What sectors does Taiho Ventures, LLC focus on?
- Taiho Ventures, LLC focuses on Biotech, Medical Devices.
- Where is Taiho Ventures, LLC located?
- Taiho Ventures, LLC is headquartered in Menlo Park, US.
- Who does Taiho Ventures, LLC co-invest with?
- Taiho Ventures, LLC most often shares deals with Pfizer Venture Investments, Canaan Partners, MPM BioImpact, among 53 tracked co-investors.
Similar investors
Capricorn Partners is a Belgium-based, partner-owned independent management company for alternative investment funds, investing in innovative companies across digital, health and clean technologies with an ESG focus.
Sofinnova is an investment firm focused on the life sciences and biotechnology sector, partnering with companies from inception through drug development, regulatory approval, company building, and IPO.
Kaiser Permanente Ventures is the corporate venture capital arm investing in healthcare companies that address real needs and deliver value for patients, providers, healthcare delivery systems, and communities.
Foresite Capital is a healthcare-focused investment firm backing companies at the intersection of technology and biotechnology to personalize healthcare and accelerate medical innovation.
Korea Investment Partners is a South Korea-based venture capital firm that invests across multiple stages from early-stage startups through growth and buyout transactions, including venture debt and mezzanine financing. The firm operates across venture capital, middle market, and growth equity investment categories.